date,ticker,timestamp,oneDayReturnPct,finalScore,modelReturnPrediction,nonFundamental,news,sentiment,uncertainty,confidence,returnLikelihood,evidenceCheckedCited,reason,metrics_EC,metrics_PCR,metrics_SD,metrics_NRI,metrics_HDM,metrics_CONTR,metrics_FRESH_NEG,metrics_CP,metrics_RD,PriceAtOpen,PriceAt1730CET,lm_fit_long,lm_fit_short,avg_volume_30d,Target_Short,Target_Long,T1_Date_IBKR
2025-12-24,INBX,2025-12-24T10:01:09.156207,-10.14,0.95,0.0,Yes,0.77,0.53,High,High,97.3,Positive Phase 2 Data,Sell the News / Oversold. Positive ChonDRAgon trial results caused surge; this drop is technical profit taking. Fundamentally stronger.,0.8,0.8,0.9,0.7,0.8,0.9,0,0.8,0.9,,,0.0402008258493657,0.0840930999508274,22405112.748999994,,,
2025-12-24,BLLN,2025-12-24T10:01:09.156207,-8.84,0.68,0.0,No,0.55,0.33,High,Medium,92.9,Q3 Revenue +117%,Revenue Growth. Q3 Revenue +117%. EPS miss is growing pains. Profitable ($5.7M net income). Rebound likely as IPO lockup fears stabilize.,0.7,0.6,0.7,0.5,0.6,0.7,0,0.6,0.7,,,0.0892700816924141,-0.0205121324967211,21724572.61783333,-0.04,0.03632354647789249,20251226
2025-12-24,ASMB,2025-12-24T10:01:09.156207,-9.08,0.55,0.0,Yes,0.68,0.33,High,Medium,92.2,Gilead Licensing Deal,Gilead Deal Validation. Gilead licensed HSV programs. Drop is counter-intuitive to fundamental derisking.,0.8,0.7,0.8,0.6,0.7,0.8,0,0.7,0.9,,,0.0975809431154686,-0.0120366035665122,5492820.724666665,0.003851851851851928,-0.003851851851851928,20251226
2025-12-24,PVLA,2025-12-24T10:01:09.156207,-8.85,0.46,0.0,Yes,0.75,0.53,High,Medium,92.7,TOIVA Trial Results,Successful Phase 2. TOIVA trial success (Dec 15) drove stock up. Drop is consolidation.,0.8,0.7,0.8,0.7,0.7,0.8,0,0.8,0.8,,,0.0689579874703583,0.0334848831780808,28988749.7075,0.020189573459715598,-0.04,20251226
2025-12-24,JFB,2025-12-24T10:01:09.156207,-9.06,-0.21,0.0,No,0.45,0.13,High,Low,60.8,Revenue growth,Low Float/Lockup. Volatile trading post-IPO lockup expiry. 119% rev growth is positive but stock weak.,0.5,0.5,0.4,0.5,0.5,0.5,0,0.5,0.5,,,-0.0099328925458177,0.0244303389811756,1035827.2006666666,-0.04,0.10185185185185197,20251226
2025-12-24,SDHC,2025-12-24T10:01:09.156207,-9.29,-0.24,0.0,No,-0.63,-0.33,High,Low,18.2,Earnings Miss Q3,Fundamental Miss. Q3 EPS $0.24 vs $0.67 est. Housing market headwinds (rates). Not a clear reversal.,0.5,0.4,0.6,0.3,0.4,0.5,1,0.3,0.5,,,0.0966462353625137,-0.0237248744916592,1605774.3520000002,-0.0005688282138794974,0.0005688282138794974,20251226
2025-12-24,FBRX,2025-12-24T10:01:09.156207,-9.15,-0.37,0.0,No,0.33,-0.2,High,Low,41.6,Historical lawsuit,History of value destruction. No immediate catalyst found for drop.,0.4,0.4,0.5,0.3,0.4,0.5,0,0.4,0.5,,,0.0123387260622808,0.0339167975962749,3435429.767166667,-0.0075921908893709636,-0.04,20251226
2025-12-24,CSIQ,2025-12-24T10:01:09.156207,-8.73,-0.49,0.0,No,-0.68,-0.47,High,Low,10.0,Tariff news,Tariff Risk. Earnings miss + Tariff headwinds. Structural issues.,0.4,0.3,0.5,0.2,0.3,0.4,1,0.2,0.7,,,0.0153766469545494,0.137607936333591,141683005.94816667,0.02500000000000004,-0.04,20251226
2025-12-24,FBYD,2025-12-24T10:01:09.156207,-9.06,-0.98,0.0,Yes,-0.64,-0.4,High,Low,4.3,Redemption rate,SPAC De-peg. 75% redemptions. Highly volatile low float.,0.3,0.3,0.2,0.2,0.3,0.3,1,0.3,0.6,,,0.013699093185311,-0.0281637550821776,3174733.324,0.05145413870246075,-0.04,20251226
2025-12-24,SMX,2025-12-24T10:01:09.156207,-11.63,-1.13,0.0,No,-0.75,-0.8,High,Low,2.1,Filings,Dilution Spiral. Continued drop post-pump. Toxic financing structure.,0.1,0.1,0.2,0.1,0.1,0.1,1,0.1,0.8,,,-0.0623145782279484,0.1741717303953104,186284785.7263333,0.17416288308740074,-0.04,20251226
2025-12-29,ASTS,2025-12-29T09:53:19.548183,-13.23,1.35,0.0,No,0.67,0.55,Low,High,98.7,58 checked / 14 cited,"The 13% drop follows a peak-cycle satellite deployment milestone, suggesting classic institutional 'sell the news' profit-taking. Despite the volatility, fundamental progress on its direct-to-cell network remains intact. Strong historical support levels and high retail sentiment suggest a technical rebound within 1-5 days as momentum traders re-enter.",0.97,0.85,0.82,0.75,0.9,0.05,0,0.68,0.7,,,-0.4635821862762838,1.1089134738811974,934618816.0283332,-0.04,0.03206191265892769,20251230
2025-12-29,QBTS,2025-12-29T09:53:19.548183,-7.18,0.72,0.0,No,0.5,0.19,Medium,Medium,92.0,45 checked / 9 cited,The decline is attributed to a broader sector rotation away from speculative quantum computing stocks. No company-specific negative filings were observed. Recent commercial milestones in quantum annealing provide a valuation floor. A technical oversold bounce is anticipated as the stock approaches its 50-day moving average.,0.75,0.72,0.68,0.55,0.8,0.1,0,0.55,0.5,,,-0.3547836616521808,0.8734611830662022,826615985.487,0.011113203993219125,-0.011113203993219125,20251230
2025-12-29,OMER,2025-12-29T09:53:19.548183,-6.57,0.48,0.0,No,0.47,0.01,High,Medium,84.9,51 checked / 11 cited,"Decline driven by binary risk sentiment ahead of upcoming clinical data updates. Regulatory environment for biotech is currently strained, causing pre-data jitters. While the fundamental pipeline is strong, the high uncertainty regarding trial outcomes makes a 1-5 day rebound purely dependent on technical oversold conditions and small-cap flows.",0.85,0.78,0.72,0.6,0.85,0.15,0,0.45,0.6,,,0.0397027007893313,0.0201908745564408,34719669.63783333,-0.04,0.023536511768255917,20251230
2025-12-29,PDEX,2025-12-29T09:53:19.548183,-6.7,0.31,0.0,No,0.34,-0.01,Medium,Low,77.7,32 checked / 5 cited,The stock suffered from low-volume slippage following a lack of news catalysts. PDEX typically exhibits high price sensitivity to small trades. Limited sourcing suggests no fundamental impairment. Rebound likelihood is moderate as the stock has a history of rapid recovery following illiquidity-driven dips.,0.53,0.4,0.45,0.3,0.6,0.0,0,0.5,0.25,,,-0.0246991286938481,-0.0526592562250741,1233321.6085,0.01806615776081409,-0.01806615776081409,20251230
2025-12-29,HYMC,2025-12-29T09:53:19.548183,-5.63,0.26,0.0,No,0.4,-0.01,Medium,Medium,76.7,42 checked / 8 cited,The dip is a direct correlation to a temporary correction in spot gold prices. Mining equities are currently showing higher beta than the underlying commodity. A rebound is contingent on a recovery in precious metals markets. Limited sourcing for idiosyncratic news indicates this is purely a macro-technical move.,0.7,0.6,0.55,0.4,0.7,0.05,0,0.48,0.45,,,-0.0340348110477779,-0.0202691855359911,65735900.72866666,-0.04,-0.04,20251230
2025-12-29,BETA,2025-12-29T09:53:19.548183,-5.22,0.04,0.0,No,0.35,-0.17,Medium,Low,62.8,38 checked / 7 cited,The fall reflects generalized selling in the electric aviation sub-sector. Market skepticism regarding long-term infrastructure timelines is weighing on growth multiples. High PCR indicates consensus on sector headwinds. Rebound potential is limited in the short window as momentum remains negative.,0.63,0.82,0.6,0.45,0.75,0.05,0,0.4,0.35,,,-0.0564911156671584,-0.0378561144008113,24395864.08633333,0.05935613682092554,-0.04,20251230
2025-12-29,MFI,2025-12-29T09:53:19.548183,-8.11,-0.28,0.0,No,0.23,-0.25,High,Low,41.7,25 checked / 4 cited,"Significant selling pressure in a low-float, HK-based ticker following a recent volatility spike. Lack of primary filings suggests a momentum unwind. High risk of further mean reversion to the downside. Confidence is low due to limited sourcing and high retail crowd concentration which creates unpredictable exit flows.",0.42,0.25,0.3,0.25,0.4,0.2,0,0.35,0.2,,,-0.0155575197124689,0.0338864621221027,1888497.849,-0.04,0.029842342342342204,20251230
2025-12-29,SMX,2025-12-29T09:53:19.548183,-9.87,-0.6,0.0,No,-0.6,-0.47,High,Medium,8.4,48 checked / 10 cited,"Post-reverse split volatility remains high. Investors are reacting negatively to potential dilution risks mentioned in recent 8-K filings. The high stock price reflects a consolidated share count rather than fundamental strength. FRESH_NEG is flagged due to primary-confirmed dilution concerns, capping rebound likelihood severely.",0.8,0.9,0.65,0.7,0.85,0.1,1,0.25,0.55,,,-0.0253320631764645,0.1790898654996969,188707043.6176667,0.20220189176616518,-0.04,20251230
2025-12-29,THH,2025-12-29T09:53:19.548183,-6.49,-0.72,0.0,No,0.17,-0.46,High,Low,18.1,18 checked / 2 cited,"Ongoing selling pressure in a newly listed entity. Very limited sourcing available for primary drivers. Sector remains unknown, complicating the fundamental anchor. The 6% drop likely reflects early investor exits or lock-up expirations. Technical rebound is improbable without a clear news catalyst or liquidity influx.",0.3,0.15,0.2,0.2,0.3,0.0,0,0.3,0.15,,,-0.058070448941597,0.0488920551680856,1863415.6504099995,0.219200659250103,-0.04,20251230
2025-12-29,PHOE,2025-12-29T09:53:19.548183,-5.38,-0.97,0.0,No,0.13,-0.43,High,Low,11.4,15 checked / 1 cited,Stock is exhibiting 'drift' behavior on extremely low volume. No relevant news or filings detected in the last 10 trading days. Limited sourcing flags this as a high-risk illiquid ticker. Rebound case is non-existent as there is no clear driver for the initial fall other than market indifference.,0.25,0.1,0.1,0.1,0.2,0.0,0,0.3,0.1,,,-0.0844233263451088,0.044623324685737,64725.281416666665,0.0006249999999999867,-0.0006249999999999867,20251230
2025-12-30,USAU,2025-12-30T09:10:00.563177,-10.12,0.66,0.0,No,0.51,0.19,Low,High,91.0,52 checked / 8 cited,"The 10% drop stems from a sector-wide consolidation in gold mining and a primary shelf registration filing. However, the sell-off is disproportionate to the underlying asset value of the CK Gold Project. Technical support levels around $19.50 suggest a mean-reversion opportunity as gold spot prices stabilize. Rebound likelihood is high due to strong fundamental anchor and high residual drop relative to peers.",0.92,0.85,0.75,0.65,0.88,0.05,0,0.55,0.4,,,-0.0709222177310512,0.0327888190557953,5580077.047666668,0.004615384615384608,-0.004615384615384608,20251231
2025-12-30,BRBR,2025-12-30T09:10:00.563177,-9.38,0.61,0.0,No,0.48,0.0,Low,High,87.9,58 checked / 12 cited,"The 9.4% drop followed a cautious analyst note regarding protein raw material costs and potential margin compression. As a market leader in protein shakes (Premier Protein), BRBR typically sees strong dip-buying from institutional holders. The sell-off provides a valuation reset. Short-term rebound case is supported by strong consumer demand resilience and fundamental sector strength.",0.95,0.78,0.82,0.68,0.9,0.05,0,0.48,0.45,,,-0.1123707062025483,0.2044873416517197,124559829.305,-0.0030018761726079493,0.0030018761726079493,20251231
2025-12-30,AUGO,2025-12-30T09:10:00.563177,-8.14,0.6,0.0,No,0.5,0.04,Low,Medium,88.4,48 checked / 6 cited,Decline driven by quarterly production update showing temporary operational headwinds at the Aranzazu mine. The 8% dip is viewed as an overreaction given the company’s dividend yield and robust cash flow from other assets. Historical patterns show rapid 3-day recovery after production misses that don't alter annual guidance. Limited sourcing on community sentiment suggests professional-led flows.,0.88,0.9,0.7,0.72,0.92,0.0,0,0.52,0.35,,,-0.0113958776344478,-0.0366125824982152,25063558.578,-0.004683140693503377,0.004683140693503377,20251231
2025-12-30,AAUC,2025-12-30T09:10:00.563177,-7.87,0.5,0.0,No,0.44,0.06,Medium,Medium,85.7,45 checked / 5 cited,"Allied Gold fell alongside the gold cohort but showed higher-than-average volume, suggesting institutional positioning rather than fundamental decay. The drop below the 50-day moving average triggered technical selling. Rebound is expected within 5 days as the company confirms Kurala Gold Project timelines. Valuation remains attractive at current levels compared to mid-tier peers.",0.85,0.82,0.68,0.6,0.85,0.1,0,0.5,0.3,,,0.0011131866352628,-0.0864212367507838,15424283.683666669,0.0004368719965050923,-0.0004368719965050923,20251231
2025-12-30,BALY,2025-12-30T09:10:00.563177,-7.88,0.42,0.0,No,0.39,-0.19,Medium,Medium,78.9,55 checked / 9 cited,"Drop is attributed to regulatory delays in Chicago and cooling M&A speculation after a period of consolidation rumors. While fundamental uncertainty persists regarding the permanent casino site, the stock is approaching historical support at $16.00. A technical bounce is likely as the RSI enters oversold territory, though long-term fundamental momentum remains neutral.",0.9,0.75,0.78,0.55,0.82,0.15,0,0.42,0.38,,,0.0254239472105886,-0.0792719968177494,2219596.7893333333,-0.04,0.019123997532387336,20251231
2025-12-30,ZBIO,2025-12-30T09:10:00.563177,-8.1,0.2,0.0,No,0.37,-0.17,High,Low,70.3,42 checked / 4 cited,"Selling pressure is likely linked to the expiration of early-investor lockups or a quiet period ending without major catalysts. ZBIO has been volatile post-IPO, and this 8% dip is characteristic of its high-beta profile. Rebound potential exists if clinical trial updates for obexelimab are reiterated. However, lack of primary news drivers keeps uncertainty at a medium level.",0.82,0.65,0.6,0.5,0.75,0.1,0,0.45,0.25,,,-0.0057829073292909,0.0576918792708078,12994774.448166665,0.0016497113005222758,-0.04,20251231
2025-12-30,GLTO,2025-12-30T09:10:00.563177,-13.27,-0.01,0.0,No,0.32,-0.32,High,Low,55.6,38 checked / 3 cited,"The 13% decline follows a period of speculative gains. No fresh negative fundamental data was found, suggesting a 'sell the news' reaction or profit taking. As a micro-cap biotech, liquidity is thin, amplifying the move. A partial rebound is probable as it reaches technical support, but limited sourcing on recent events suggests high idiosyncratic risk.",0.75,0.55,0.55,0.45,0.65,0.05,0,0.4,0.2,,,-0.0042061400427883,0.0412531571461381,3489927.248666667,-0.04,0.0004347826086957201,20251231
2025-12-30,SMX,2025-12-30T09:10:00.563177,-27.03,-0.27,0.0,No,0.38,-0.36,High,Low,42.7,40 checked / 7 cited,"Severe drop of 27% is tied to extreme volatility typical of low-float, post-reverse-split entities. SMX is frequently subject to retail-driven price swings. While the 1-5 day rebound potential is mathematically high due to the magnitude of the drop, the lack of fundamental anchoring and high risk of further dilution via ATM offerings makes this a high-uncertainty technical play only.",0.8,0.5,0.65,0.7,0.8,0.2,0,0.35,0.3,,,-0.0395987320251805,0.310381937987837,190162756.38766667,0.6261147953350102,-0.04,20251231
2025-12-30,RARE,2025-12-30T09:10:00.563177,-42.32,-0.75,0.0,No,-0.6,-0.72,Low,High,4.9,60 checked / 22 cited,Fresh Negative Fundamental Shock: The 42% collapse follows primary-source confirmation of a failed Phase 3 trial for a lead asset. Such events typically represent permanent value impairment rather than a temporary dip. Rebound likelihood is low as analysts downgrade price targets and the cash runway becomes a central concern. Dead cat bounces are possible but statistically improbable within a 5-day window.,1.0,0.98,0.92,0.95,0.98,0.02,1,0.1,0.75,,,-0.0051482163122969,0.0849871982501952,68681304.79816668,-0.019955654101995533,0.019955654101995533,20251231
2025-12-30,VRM,2025-12-30T09:10:00.563177,-9.69,-1.06,0.0,No,-0.63,-0.65,Medium,Medium,2.7,52 checked / 11 cited,"The 9.7% drop reflects ongoing skepticism regarding the company's pivot to United Auto Credit (UACC) and the wind-down of its e-commerce business. High short interest and negative momentum continue to plague the stock. Without a fresh positive catalyst or a surprise in financing terms, the stock is likely to continue its drift lower. Rebound case is the weakest in the cohort.",0.92,0.88,0.85,0.62,0.88,0.1,1,0.15,0.45,,,0.034880709871853,-0.0555015081735019,72778.38275862068,-0.03219106957424701,0.03219106957424701,20251231
2025-12-31,CORT,2025-12-31T09:15:41.554840,-12.06,1.1,0.0,No,0.55,-0.05,Low,High,95.5,52 checked / 18 cited,"Shares fell on news of a court ruling regarding patent litigation for Korlym. Historically, CORT is highly resilient with strong cash flow and market share. The 12% drop appears to be a typical legal-uncertainty overreaction. Fundamentals remain intact, and institutional buyers frequently use these litigation-driven dips to accumulate, suggesting a high probability of a mean-reversion bounce within 1-5 days.",0.92,0.88,0.75,0.82,0.9,0.05,0,0.45,0.65,,,-0.0873734864392459,0.1044164696636811,97813990.12850004,-0.04,0.06465997770345597,20260102
2025-12-31,BLBD,2025-12-31T09:15:41.554840,-6.99,0.93,0.0,No,0.58,0.33,Low,High,95.7,45 checked / 12 cited,"The 7% decline is largely attributed to profit-taking following a strong year-to-date run and a recent secondary offering or insider sale signal. Demand for electric school buses remains a powerful tailwind. This is a technical 'breather' in an uptrend. Given the strong order backlog and structural industrial growth, a technical rebound to fill the gap is expected as RSI hits oversold levels.",0.85,0.82,0.6,0.7,0.85,0.1,0,0.6,0.55,,,-0.086014442396754,0.0234622191709404,22324877.319166664,0.019911968140851034,-0.019911968140851034,20260102
2025-12-31,FFIC,2025-12-31T09:15:41.554840,-8.94,0.35,0.0,No,0.36,-0.34,Low,Medium,73.3,41 checked / 14 cited,"Fell nearly 9% due to regional banking sector weakness and margin pressure concerns cited in recent analyst notes. FFIC maintains a solid deposit base but interest rate sensitivity is weighing on short-term sentiment. At $15.38, it is near a 52-week support zone. The rebound case is a value-based correction as the stock trades below book value. Note: Price is near the $15 constraint threshold.",0.78,0.75,0.65,0.6,0.8,0.05,0,0.3,0.5,,,0.0103952632678155,-0.0590136111352113,6372827.813666667,0.003947368421052548,-0.003947368421052548,20260102
2025-12-31,GLSI,2025-12-31T09:15:41.554840,-11.54,0.32,0.0,No,0.37,-0.16,Medium,Medium,76.1,38 checked / 9 cited,Drop likely caused by high-beta volatility ahead of upcoming Phase 3 FLAMINGO-01 trial updates. Clinical-stage biotech often sees 'shakeouts' of retail hands before pivotal news. The company remains well-capitalized for its current trials. Historical price action shows sharp recoveries after 10%+ newsless dips. Limited sourcing on specific fresh negative catalysts suggests this is flows-driven. Rebound case relies on speculative support levels.,0.63,0.55,0.45,0.5,0.7,0.15,0,0.4,0.4,,,0.012677183551836,-0.1070369871540947,8879118.744500002,0.0850563909774437,-0.04,20260102
2025-12-31,LYEL,2025-12-31T09:15:41.554840,-12.37,0.18,0.0,No,0.3,-0.19,Medium,Medium,68.1,33 checked / 7 cited,"Correction follows a period of clinical trial data digestion. Market may be discounting the speed of the cell therapy pipeline. The 12% move is idiosyncratic and lacks a definitive primary-source 'fail' event today. Usually, such moves in well-funded biotech see a 3-5% corrective bounce within 48 hours as technical indicators reset. Limited sourcing on new negative events suggests institutional rebalancing.",0.55,0.6,0.5,0.4,0.65,0.1,0,0.35,0.35,,,0.0150004110281689,-0.1296630277555435,3003711.823333333,0.07471264367816091,-0.04,20260102
2025-12-31,NNNN,2025-12-31T09:15:41.554840,-7.41,-0.06,0.0,No,0.46,-0.06,High,Low,65.1,22 checked / 4 cited,The 7% drop is likely a result of low-float volatility and profit taking after a recent listing-related run. No significant SEC filings or press releases were issued today to justify the move fundamentals-wise. These 'new' tickers are prone to high mean-reversion but carry significant 'sigma' risk. Limited sourcing due to novelty of the listing. Rebound likely if it holds the $28 psychological support level.,0.37,0.4,0.3,0.7,0.5,0.05,0,0.5,0.25,,,-0.045471184225921,0.0241883312349227,1020709.4156666668,-0.04,-0.04,20260102
2025-12-31,WSHP,2025-12-31T09:15:41.554840,-10.81,-0.32,0.0,No,0.33,-0.09,Medium,Low,46.5,25 checked / 5 cited,"WSHP is experiencing a momentum reversal after an unsustainable vertical climb. At $95, the 10% drop is a breakdown of the parabolic trend. Such high-priced, low-float stocks often experience 'cascading' sell-offs before finding buyers. The fundamental anchor is extremely weak relative to the market cap. Rebound probability is low as the 'hype' cycle cools. Limited sourcing regarding institutional support.",0.42,0.3,0.35,0.5,0.5,0.05,0,0.4,0.2,,,-0.0583339443648016,-0.0187383959799338,3820376.0096666655,-0.02040816326530612,0.02040816326530612,20260102
2025-12-31,THH,2025-12-31T09:15:41.554840,-15.36,-0.39,0.0,No,0.29,-0.26,High,Low,38.4,19 checked / 3 cited,"Sharp 15% decline on very low volume, characteristic of a liquidity trap or a single large seller exiting. No material news found. Without a catalyst, the 'non-fundamental' nature of the drop makes it a candidate for a technical reversal, but the lack of transparent sourcing and low float makes this high risk. LIMITED SOURCING available to verify long-term recovery potential.",0.32,0.2,0.25,0.3,0.4,0.1,0,0.45,0.15,,,-0.0158115437651623,0.0297812826873326,2016117.5750766664,-0.04,-0.04,20260102
2025-12-31,GLTO,2025-12-31T09:15:41.554840,-24.65,-0.47,0.0,No,-0.6,-0.67,Low,High,9.1,48 checked / 15 cited,"Galecto crashed 24% after disappointing clinical results or a pipeline reprioritization news. A 'Fresh Negative' fundamental shock is confirmed. Historically, such significant clinical misses require a long period of consolidation. While an oversold bounce is possible, the 'dead cat bounce' risk is high. PCR is high as the primary driver is a company-specific release. Rebound likelihood is tempered by the gravity of the data miss.",0.8,0.95,0.6,0.9,0.95,0.0,1,0.15,0.7,,,-0.0258317216247345,-0.0220774480222185,3192968.115666667,0.10647010647010652,-0.04,20260102
2025-12-31,SMX,2025-12-31T09:15:41.554840,-39.43,-1.03,0.0,No,-0.6,-0.79,Medium,Medium,2.6,55 checked / 14 cited,"Massive 39% plunge follows dilutive financing and the conversion of preferred shares into common stock. This 'fresh negative' fundamental shock creates significant overhead supply. The company’s history of dilution and weak balance sheet make a meaningful 1-5 day rebound unlikely, as the market must absorb the new float. Limited sourcing on future catalysts. Avoidance is favored over a rebound play here.",0.9,0.92,0.55,0.85,0.9,0.0,1,0.1,0.6,,,-0.0360625417946867,0.0765666560514205,192175937.61766663,-0.04,-0.04,20260102
2026-01-02,QXO,2026-01-02T10:46:07.075648,-8.06,0.85,0.0,No,0.43,-0.19,Low,High,90.7,52 checked / 14 cited,"The drop stems from cooling momentum and a technical pullback after a significant multi-month rally led by management change sentiment. Rebound Case: The leadership of Brad Jacobs provides a strong fundamental anchor and institutional confidence. The current price represents a mean-reversion opportunity as the stock approaches support levels, with liquidity remains high for a quick recovery.",0.87,0.85,0.7,0.6,0.8,0.05,0,0.45,0.4,,,-0.1290040622897522,0.1495143318600854,132856226.78700002,-0.04,0.13825109916951647,20260105
2026-01-02,TAYD,2026-01-02T10:46:07.075648,-7.18,0.65,0.0,No,0.4,-0.51,Medium,Medium,82.3,48 checked / 9 cited,"The decline followed an earnings update that showed moderate margin pressure despite robust revenue. Rebound Case: The company maintains a strong balance sheet and niche market dominance in structural damping. Historically, TAYD exhibits quick recovery post-earnings dips as value investors step in. Limited sourcing on community sentiment suggests the move was driven primarily by institutional repositioning.",0.8,0.9,0.6,0.75,0.85,0.1,0,0.35,0.3,,,0.0025739391821851,-0.1399878461189921,510653.27333333343,-0.04,0.03923076923076919,20260105
2026-01-02,NUTX,2026-01-02T10:46:07.075648,-9.19,0.35,0.0,No,0.22,-0.49,High,Low,66.4,45 checked / 7 cited,"The slide is part of a broader correction in high-volatility healthcare services. Rebound Case: NUTX often experiences sharp reversals after 8-10% intraday drops due to high retail participation and technical support levels. However, lack of fresh positive catalysts suggests any rebound may be short-lived. Limited sourcing on fundamental shifts implies the move is primarily liquidity-driven.",0.75,0.6,0.45,0.4,0.5,0.0,0,0.25,0.25,,,-0.0354004802029174,0.0060876596122223,31729534.33333333,-0.04,0.13677358106733564,20260105
2026-01-02,NGNE,2026-01-02T10:46:07.075648,-7.29,0.17,0.0,No,0.27,-0.57,Low,Medium,57.7,44 checked / 8 cited,"The decline reflects a routine pullback following recent gains in gene therapy stocks. Rebound Case: Neurogene's pipeline updates remain the primary catalyst. Without fresh negative clinical data, the stock should find support near the $20 mark. However, the lack of immediate catalysts (Limited sourcing) limits the probability of a significant 5-day surge.",0.73,0.7,0.55,0.45,0.6,0.0,0,0.3,0.25,,,-0.0298513718196723,-0.0821751703632767,3839202.812,0.09077454366058213,-0.04,20260105
2026-01-02,CORT,2026-01-02T10:46:07.075648,-10.52,0.13,0.0,No,-0.6,-0.81,Medium,High,22.8,60 checked / 18 cited,"The drop was triggered by a legal setback in the Korlym patent litigation against Teva Pharmaceuticals. Rebound Case: While the legal news is a negative fundamental shock (FRESH_NEG), Corcept's existing revenue stream remains stable in the near term. The 10% drop likely overprices the immediate impact of generic entry, offering a short-term bounce as the market digests the full legal timeline.",1.0,0.95,0.85,0.9,0.95,0.15,1,0.2,0.6,,,-0.0514137636353057,0.0897970964850991,105169623.86983338,0.08363922391190345,-0.04,20260105
2026-01-02,APLM,2026-01-02T10:46:07.075648,-11.02,0.09,0.0,No,0.15,-0.67,Medium,Medium,47.8,41 checked / 6 cited,"General biotech sector weakness combined with low-volume selling pressure. Rebound Case: APLM is susceptible to wide swings on minimal news. The 11% drop lacks a confirmed fundamental driver in SEC filings (Limited sourcing), suggesting it may be an idiosyncratic liquidity event. A partial recovery is likely if broader biotech sentiment improves over the next 5 days.",0.68,0.5,0.4,0.3,0.45,0.05,0,0.2,0.2,,,-0.0212612348466321,-0.1427381180873952,522154.5551666666,0.039939332659251904,-0.04,20260105
2026-01-02,ASPC,2026-01-02T10:46:07.075648,-22.33,0.07,0.0,No,0.17,-0.8,High,Low,45.2,32 checked / 4 cited,"The sharp drop is indicative of SPAC redemption volatility or a failed deal rumor. Rebound Case: SPACs trading well above NAV often see violent corrections. A rebound depends on the clarification of merger terms. Current lack of primary source filings for the drop (Limited sourcing) suggests a panic exit by a large holder, which could stabilize quickly.",0.53,0.4,0.3,0.5,0.4,0.0,0,0.15,0.15,,,-0.010006238626941,-0.0257302049519396,14894736.713864,0.12403895438236809,-0.04,20260105
2026-01-02,FBYD,2026-01-02T10:46:07.075648,-9.03,-0.17,0.0,No,0.1,-0.86,High,Low,29.5,38 checked / 5 cited,"The stock dropped to its lowest level since August, testing the $15.00 psychological support. Rebound Case: The price sits right at the universe constraint threshold (Price filter noted); if support holds, a technical bounce is possible. However, ongoing concerns regarding the company's long-term capital needs and low float create high uncertainty. Limited sourcing suggests low institutional interest at this level.",0.63,0.55,0.4,0.35,0.5,0.1,0,0.1,0.2,,,-0.0228931247812379,0.0001712370432498,3402591.245,-0.04,-0.024113475177304954,20260105
2026-01-02,AFJK,2026-01-02T10:46:07.075648,-39.12,-0.79,0.0,No,-0.98,-1.0,High,Low,2.3,30 checked / 3 cited,"The massive drop is characteristic of a 'low-float rug pull' or the expiration of a price-support mechanism following a speculative surge. Rebound Case: Rebounds in these scenarios are purely technical and often fail to regain 20% of the loss. With FRESH_NEG fundamentals regarding price stability and Limited sourcing on actual business news, the outlook is bearish.",0.5,0.3,0.2,0.8,0.3,0.05,1,-0.4,0.1,,,0.0497886833108385,-0.054612619426713,29343767.81810666,-0.04,0.07230538922155687,20260105
2026-01-02,SMX,2026-01-02T10:46:07.075648,-62.61,-1.5,0.0,No,-1.09,-1.0,Medium,High,0.4,55 checked / 12 cited,"The 62% crash followed a 1-for-75 reverse stock split, leading to massive technical liquidation and dilution fears. Rebound Case: Post-split crashes are often fundamental re-ratings of struggling micro-caps. While extremely oversold, the FRESH_NEG status of the corporate action and primary confirmation of the split suggest a permanent loss of value rather than a rebound opportunity. Limited sourcing on future catalysts.",0.92,0.95,0.65,0.95,0.9,0.2,1,-0.8,0.5,,,-0.0244106366914338,0.1392120498789791,197554124.01933336,0.14208456243854478,-0.04,20260105
2026-01-05,KVYO,2026-01-05T11:38:59.700097,-9.84,1.0,0.0,No,0.56,0.25,Low,High,95.8,58 checked / 12 cited,"The 9.8% decline follows conservative forward guidance despite an earnings and revenue beat in the recent quarter. OSINT indicates institutional accumulation during the dip and a consensus analyst view that the platform's expansion into SMS and international markets remains intact. This is a classic fundamental overreaction. A 1-5 day rebound is likely as technical support holds near the $28.50 level. Limited sourcing observed in community channels, but high professional coverage.",0.97,0.85,0.72,0.65,0.88,0.05,0,0.62,0.45,,,-0.0945255383791873,0.0867439214773392,68661103.90413792,-0.0013793103448275568,0.0013793103448275568,20260106
2026-01-05,RHLD,2026-01-05T11:38:59.700097,-9.97,0.78,0.0,No,0.41,-0.02,Medium,Medium,90.8,42 checked / 8 cited,"Shares fell on a high-volume block trade likely associated with institutional rebalancing. No fundamental regulatory filings (8-K/10-Q) suggest an operational decline. OSINT shows stable sentiment and no adverse litigation. Given the high price point and low retail float, this technical drop often precedes a mean-reversion move as liquidity providers fill the gap. Rebound probability is high due to lack of fresh negative fundamental shocks.",0.7,0.7,0.6,0.4,0.75,0.0,0,0.55,0.3,,,0.0187372453759392,-0.1283596768413079,16699779.88172414,-0.04,0.09286486486486491,20260106
2026-01-05,RDVT,2026-01-05T11:38:59.700097,-9.8,0.71,0.0,No,0.42,0.01,Medium,Medium,89.6,51 checked / 10 cited,The sell-off was triggered by profit-taking following a multi-week rally rather than specific negative news. Primary filings remain positive regarding IDI and FOREWARN product growth. OSINT tracking indicates the ticker entered an overbought RSI state prior to today. Rebound case is supported by strong fundamental anchors and a lack of competitive entry news. The dip provides a technical entry for momentum players.,0.85,0.65,0.55,0.5,0.8,0.1,0,0.5,0.35,,,0.0196048278610643,-0.1102875102203942,5891036.07586207,0.011314350367716414,-0.011314350367716414,20260106
2026-01-05,NUTX,2026-01-05T11:38:59.700097,-10.73,0.52,0.0,No,0.35,-0.07,High,Low,83.5,45 checked / 6 cited,Drop is likely linked to broader pressure in micro-cap healthcare providers and technical exhaustion following recent volatility. No SEC filings indicate new financing or dilution today. OSINT signals high retail discussion but low professional analyst coverage. Rebound case relies on high volatility and mean reversion towards the 20-day moving average. High price-per-share suggests less retail 'noise' but wider spreads.,0.75,0.4,0.4,0.45,0.7,0.15,0,0.45,0.25,,,0.0119580725980115,0.0635697938332429,29990121.997241378,-0.04,0.03553146642577523,20260106
2026-01-05,CTEV,2026-01-05T11:38:59.700097,-21.26,-0.02,0.0,No,-0.54,-0.23,High,Low,29.8,38 checked / 5 cited,"Fell 21.3% on news of a private placement or potential secondary offering rumored in community channels, though not yet fully detailed in an 8-K. The magnitude of the drop reflects liquidity sensitivity common in new listings. OSINT suggests a 'sell the news' event after a recent IPO run-up. Rebound case is moderate as the stock seeks a valuation floor. Limited sourcing on primary drivers increases uncertainty.",0.63,0.5,0.45,0.7,0.65,0.2,1,0.35,0.2,,,0.0782445685064248,-0.0234478189131946,10097743.409310345,-0.04,0.0745509996611318,20260106
2026-01-05,AFJK,2026-01-05T11:38:59.700097,-11.17,-0.21,0.0,No,0.22,-0.34,High,Low,42.4,30 checked / 2 cited,"The 11.2% drop follows a period of extreme illiquidity and low-volume price inflation. OSINT investigation shows virtually no news or social media discussion, suggesting a single large seller cleared the bid. Without a fundamental catalyst, the stock is prone to continued drift. Rebound is unlikely without fresh news. Limited sourcing reported. Price remains high, reducing retail interest in the dip.",0.5,0.3,0.2,0.2,0.3,0.0,0,0.4,0.1,,,-0.0703782803178597,0.0273163400045806,31670141.743685704,-0.04,0.023178807947019868,20260106
2026-01-05,ASPC,2026-01-05T11:38:59.700097,-17.13,-0.24,0.0,No,0.21,-0.44,Medium,Low,38.1,40 checked / 4 cited,"Significant drop tied to SPAC redemption risks or lack of progress on a definitive merger agreement. OSINT shows community frustration with the lack of transparency from the sponsor. These vehicles often trade close to trust value; a drop of this magnitude suggests a break in confidence or a large shareholder exiting. Rebound depends entirely on merger news, which is currently non-existent.",0.67,0.45,0.35,0.3,0.5,0.1,0,0.32,0.15,,,-0.0589768711274987,-0.0458639953945688,16303514.89593913,0.01720958819913948,-0.04,20260106
2026-01-05,ESHA,2026-01-05T11:38:59.700097,-14.11,-0.4,0.0,No,0.18,-0.48,Medium,Low,28.9,35 checked / 3 cited,Fell 14.1% on high volume. Price filter alert: ticker is near the $15 threshold. OSINT indicates this is likely a redemption-driven exit as a deadline approaches. SPACs at this stage rarely rebound significantly until a target is announced or trust liquidations are clarified. Limited sourcing available for this specific move. Confidence is low due to price proximity to the $15 floor.,0.58,0.4,0.3,0.25,0.4,0.05,0,0.3,0.12,,,-0.0775637547548439,-0.0588098990339792,6828568.066431999,-0.04,-0.04,20260106
2026-01-05,GLTO,2026-01-05T11:38:59.700097,-10.65,-0.91,0.0,No,-0.66,-0.43,High,Medium,4.2,55 checked / 7 cited,"The 10.7% drop is linked to fresh negative OSINT regarding pipeline delays or clinical trial enrollment difficulties. Biotech stocks frequently see cascading selling when primary catalysts are deferred. PCR is low because no formal SEC update has been filed today, but news sentiment is bearish. Rebound probability is low until data readouts are confirmed or a strategic update is issued.",0.92,0.35,0.5,0.55,0.6,0.25,1,0.22,0.2,,,0.0526961449419164,0.040998384496399,2828364.4586206903,-0.04,0.032624113475177366,20260106
2026-01-05,FBRX,2026-01-05T11:38:59.700097,-13.26,-1.27,0.0,No,-0.65,-0.54,High,Medium,1.9,50 checked / 9 cited,Significant selling pressure followed a fundamental shock involving clinical asset efficacy or financing concerns. OSINT reveals a bearish professional consensus after a primary research note circulated. Fresh negative fundamental driver (FRESH_NEG=1) is confirmed by primary commentary. Recovery is likely to be hindered by 'trapped' longs at higher levels. Limited sourcing on the rebound case makes this the least likely candidate for a 1-5 day bounce.,0.83,0.55,0.45,0.65,0.55,0.3,1,0.18,0.25,,,0.0175502663904072,0.0078263267484343,3846577.933620691,-0.04,0.037593984962406075,20260106
2026-01-06,SITM,2026-01-06T13:05:26.510892,-11.29,1.0,3.119903371665181,No,0.46,-0.19,Low,High,93.1,60 checked / 14 cited,"Dipped on broader semiconductor profit-taking and technical resistance at recent highs. OSINT confirms no company-specific negative catalysts. Rebound case is strong based on fundamental timing-chip market leadership and mean reversion as prices stabilize above key support levels. Limited sourcing noted for fresh idiosyncratic news, suggesting a momentum-driven drawdown.",0.95,0.88,0.72,0.35,0.92,0.05,0,0.68,0.25,,,-0.1000927171755329,0.1334997072954455,118537466.37344828,-0.014504336500606915,0.014504336500606915,20260107
2026-01-06,AAOI,2026-01-06T13:05:26.510892,-14.77,0.83,3.0496352894609533,No,0.43,-0.2,Medium,High,90.2,60 checked / 18 cited,"Retracted sharply following a parabolic run in the high-speed optical networking space. The move appears technical, driven by institutional rebalancing. Rebound likelihood is high within 5 days as the 800G product cycle remains a significant fundamental driver. Limited sourcing on primary negative filings suggests a temporary liquidity vacuum rather than structural impairment.",0.9,0.75,0.65,0.4,0.88,0.1,0,0.58,0.3,,,-0.1099616777082896,0.1538989024186919,161595156.05206898,-0.04,0.01371870005327652,20260107
2026-01-06,CRNX,2026-01-06T13:05:26.510892,-12.4,0.62,6.643884976006417,No,0.39,-0.54,Medium,Medium,80.3,58 checked / 12 cited,Experienced selling pressure following recent clinical momentum. OSINT identifies no new adverse events; the move reflects profit-taking post-acromegaly data excitement. Rebound case is supported by a strong cash position and mid-term pipeline milestones. Uncertainty is medium given the high-beta nature of the biotech sector during macro volatility.,0.92,0.82,0.68,0.45,0.85,0.05,0,0.52,0.2,,,-0.0048256222105125,-0.0561826468416034,56275015.35206895,-0.04,0.05000000000000013,20260107
2026-01-06,CAPR,2026-01-06T13:05:26.510892,-11.11,0.43,6.709467583022656,No,0.33,-0.6,Medium,Medium,70.7,52 checked / 10 cited,"Declined on news of a potential secondary offering or capital raise speculation following recent price appreciation in the DMD therapeutic space. While dilutive in the short term, the fundamental derisking of CAP-1002 provides a floor. Expected to stabilize as financing details are confirmed. Limited sourcing on definitive filing timing.",0.85,0.65,0.55,0.5,0.8,0.15,0,0.4,0.18,,,-0.0312406898908503,0.0291975698860065,107941972.43862069,-0.008819018404907992,0.008819018404907992,20260107
2026-01-06,CTEV,2026-01-06T13:05:26.510892,-13.17,0.18,7.059165432534282,No,0.26,-0.73,High,Medium,54.6,45 checked / 6 cited,"Drop likely linked to thin liquidity and post-listing volatility. No primary SEC filings indicate fundamental deterioration today. Rebound potential exists as a 'low-float' reversal play, though uncertainty remains high due to limited analyst coverage and high institutional concentration. Limited sourcing available for intraday retail sentiment drivers.",0.65,0.5,0.4,0.2,0.7,0.0,0,0.45,0.15,,,0.0384211134199465,-0.0298743587097321,9907773.078965517,-0.04,0.04979119820109222,20260107
2026-01-06,GHRS,2026-01-06T13:05:26.510892,-17.84,0.17,8.417356148633623,No,0.23,-0.92,Medium,Medium,48.4,50 checked / 8 cited,"Sharp decline suggests investor impatience regarding Phase 2b trial timelines for GH001. No direct negative readout was found, indicating the move is largely technical and liquidity-driven within the depression-treatment subsector. Rebound case relies on upcoming trial updates. High volatility and limited sourcing for immediate catalysts suggest a cautious 5-day outlook.",0.8,0.7,0.5,0.3,0.75,0.05,0,0.35,0.15,,,0.0105491846327615,-0.1258770510690953,6702270.248793106,-0.04,0.2570028011204482,20260107
2026-01-06,SRZN,2026-01-06T13:05:26.510892,-10.83,-0.15,8.782080949713848,No,0.18,-1.0,High,Low,30.2,40 checked / 5 cited,Micro-cap volatility exacerbated by low trading volume. OSINT shows general biotech sector weakness rather than idiosyncratic failure. Rebound likelihood is constrained by lack of immediate primary news and low institutional support. Limited sourcing on retail interest prevents a high-confidence reversal call.,0.6,0.55,0.35,0.25,0.65,0.0,0,0.3,0.12,,,-0.015849155009762,0.0106122544395469,2107814.265,-0.04,0.12191011235955046,20260107
2026-01-06,ASPC,2026-01-06T13:05:26.510892,-12.4,-0.58,7.882303544971879,No,0.08,-1.0,Medium,Low,13.1,42 checked / 4 cited,"Drop likely due to arbitrage activity or redemption news typical of late-stage SPAC cycles. Non-fundamental in nature, but structural constraints often prevent a rapid 5-day rebound. Rebound likelihood is low as liquidity remains focused on merger outcomes rather than price appreciation.",0.7,0.4,0.3,0.15,0.6,0.1,0,0.2,0.1,,,-0.0617197461118734,-0.0019688153354172,15677478.456525,-0.04,0.04275686024250159,20260107
2026-01-06,PVLA,2026-01-06T13:05:26.510892,-11.9,-0.97,9.168696137833518,No,-0.78,-1.0,High,Low,2.0,48 checked / 7 cited,Post-reverse-split volatility continues to drive significant price swings. OSINT suggests persistent selling from retail holders following the 1-for-25 split. Rebound case is hampered by a lack of fundamental anchors and technical breakdown. Limited sourcing on pipeline progress increases uncertainty.,0.75,0.45,0.32,0.35,0.55,0.2,1,0.15,0.14,,,-0.0018653861611235,0.0544992946265897,29119072.110344823,-0.04,0.07627570043677422,20260107
2026-01-06,SMX,2026-01-06T13:05:26.510892,-13.89,-1.33,10.112013391467666,No,-0.79,-1.0,High,Low,0.9,55 checked / 9 cited,Ongoing downward pressure following technical adjustments and persistent dilution concerns. Non-fundamental volatility is high due to extremely low trading volume and high retail concentration. The drop is likely structural; a short-term rebound is highly speculative with significant downside risk. Limited sourcing on recent corporate actions.,0.82,0.35,0.28,0.4,0.5,0.25,1,0.1,0.16,,,-0.1011208386756805,0.3017461863149001,205616478.53241372,-0.04,0.8710743801652895,20260107
2026-01-06,SITM,2026-01-06T13:24:11.075431,-11.29,1.0,0.0311990337166518,No,0.46,-0.19,Low,High,93.1,60 checked / 14 cited,"Dipped on broader semiconductor profit-taking and technical resistance at recent highs. OSINT confirms no company-specific negative catalysts. Rebound case is strong based on fundamental timing-chip market leadership and mean reversion as prices stabilize above key support levels. Limited sourcing noted for fresh idiosyncratic news, suggesting a momentum-driven drawdown.",0.95,0.88,0.72,0.35,0.92,0.05,0,0.68,0.25,,,-0.1000927171755329,0.1334997072954455,118537466.37344828,-0.014504336500606915,0.014504336500606915,20260107
2026-01-06,AAOI,2026-01-06T13:24:11.075431,-14.77,0.83,0.0304963528946095,No,0.43,-0.2,Medium,High,90.2,60 checked / 18 cited,"Retracted sharply following a parabolic run in the high-speed optical networking space. The move appears technical, driven by institutional rebalancing. Rebound likelihood is high within 5 days as the 800G product cycle remains a significant fundamental driver. Limited sourcing on primary negative filings suggests a temporary liquidity vacuum rather than structural impairment.",0.9,0.75,0.65,0.4,0.88,0.1,0,0.58,0.3,,,-0.1099616777082896,0.1538989024186919,161595156.05206898,-0.04,0.01371870005327652,20260107
2026-01-06,CRNX,2026-01-06T13:24:11.075431,-12.4,0.62,0.0664388497600641,No,0.39,-0.54,Medium,Medium,80.3,58 checked / 12 cited,Experienced selling pressure following recent clinical momentum. OSINT identifies no new adverse events; the move reflects profit-taking post-acromegaly data excitement. Rebound case is supported by a strong cash position and mid-term pipeline milestones. Uncertainty is medium given the high-beta nature of the biotech sector during macro volatility.,0.92,0.82,0.68,0.45,0.85,0.05,0,0.52,0.2,,,-0.0048256222105125,-0.0561826468416034,56275015.35206895,-0.04,0.05000000000000013,20260107
2026-01-06,CAPR,2026-01-06T13:24:11.075431,-11.11,0.43,0.0670946758302265,No,0.33,-0.6,Medium,Medium,70.7,52 checked / 10 cited,"Declined on news of a potential secondary offering or capital raise speculation following recent price appreciation in the DMD therapeutic space. While dilutive in the short term, the fundamental derisking of CAP-1002 provides a floor. Expected to stabilize as financing details are confirmed. Limited sourcing on definitive filing timing.",0.85,0.65,0.55,0.5,0.8,0.15,0,0.4,0.18,,,-0.0312406898908503,0.0291975698860065,107941972.43862069,-0.008819018404907992,0.008819018404907992,20260107
2026-01-06,CTEV,2026-01-06T13:24:11.075431,-13.17,0.18,0.0705916543253428,No,0.26,-0.73,High,Medium,54.6,45 checked / 6 cited,"Drop likely linked to thin liquidity and post-listing volatility. No primary SEC filings indicate fundamental deterioration today. Rebound potential exists as a 'low-float' reversal play, though uncertainty remains high due to limited analyst coverage and high institutional concentration. Limited sourcing available for intraday retail sentiment drivers.",0.65,0.5,0.4,0.2,0.7,0.0,0,0.45,0.15,,,0.0384211134199465,-0.0298743587097321,9907773.078965517,-0.04,0.04979119820109222,20260107
2026-01-06,GHRS,2026-01-06T13:24:11.075431,-17.84,0.17,0.0841735614863362,No,0.23,-0.92,Medium,Medium,48.4,50 checked / 8 cited,"Sharp decline suggests investor impatience regarding Phase 2b trial timelines for GH001. No direct negative readout was found, indicating the move is largely technical and liquidity-driven within the depression-treatment subsector. Rebound case relies on upcoming trial updates. High volatility and limited sourcing for immediate catalysts suggest a cautious 5-day outlook.",0.8,0.7,0.5,0.3,0.75,0.05,0,0.35,0.15,,,0.0105491846327615,-0.1258770510690953,6702270.248793106,-0.04,0.2570028011204482,20260107
2026-01-06,SRZN,2026-01-06T13:24:11.075431,-10.83,-0.15,0.0878208094971384,No,0.18,-1.0,High,Low,30.2,40 checked / 5 cited,Micro-cap volatility exacerbated by low trading volume. OSINT shows general biotech sector weakness rather than idiosyncratic failure. Rebound likelihood is constrained by lack of immediate primary news and low institutional support. Limited sourcing on retail interest prevents a high-confidence reversal call.,0.6,0.55,0.35,0.25,0.65,0.0,0,0.3,0.12,,,-0.015849155009762,0.0106122544395469,2107814.265,-0.04,0.12191011235955046,20260107
2026-01-06,ASPC,2026-01-06T13:24:11.075431,-12.4,-0.58,0.0788230354497187,No,0.08,-1.0,Medium,Low,13.1,42 checked / 4 cited,"Drop likely due to arbitrage activity or redemption news typical of late-stage SPAC cycles. Non-fundamental in nature, but structural constraints often prevent a rapid 5-day rebound. Rebound likelihood is low as liquidity remains focused on merger outcomes rather than price appreciation.",0.7,0.4,0.3,0.15,0.6,0.1,0,0.2,0.1,,,-0.0617197461118734,-0.0019688153354172,15677478.456525,-0.04,0.04275686024250159,20260107
2026-01-06,PVLA,2026-01-06T13:24:11.075431,-11.9,-0.97,0.0916869613783351,No,-0.78,-1.0,High,Low,2.0,48 checked / 7 cited,Post-reverse-split volatility continues to drive significant price swings. OSINT suggests persistent selling from retail holders following the 1-for-25 split. Rebound case is hampered by a lack of fundamental anchors and technical breakdown. Limited sourcing on pipeline progress increases uncertainty.,0.75,0.45,0.32,0.35,0.55,0.2,1,0.15,0.14,,,-0.0018653861611235,0.0544992946265897,29119072.110344823,-0.04,0.07627570043677422,20260107
2026-01-06,SMX,2026-01-06T13:24:11.075431,-13.89,-1.33,0.1011201339146766,No,-0.79,-1.0,High,Low,0.9,55 checked / 9 cited,Ongoing downward pressure following technical adjustments and persistent dilution concerns. Non-fundamental volatility is high due to extremely low trading volume and high retail concentration. The drop is likely structural; a short-term rebound is highly speculative with significant downside risk. Limited sourcing on recent corporate actions.,0.82,0.35,0.28,0.4,0.5,0.25,1,0.1,0.16,,,-0.1011208386756805,0.3017461863149001,205616478.53241372,-0.04,0.8710743801652895,20260107
2026-01-07,WVE,2026-01-07T12:47:36.372093,-20.47,1.1,-0.0207990984520772,No,0.71,0.46,High,Medium,97.8,10 checked / 5+ relevant,"Sell-the-news reaction to Phase 1 obesity data. Despite analyst upgrades and positive results, stock fell (bearish divergence).",0.6,0.8,0.8,0.7,0.6,0.8,0,0.7,0.9,,,0.0547123027594593,0.0952482049698612,184281916.83833328,,,
2026-01-07,ACFN,2026-01-07T12:47:36.372093,-9.21,0.8,-0.0441902058007544,No,0.44,0.53,Medium,Medium,94.8,10 checked / 5+ relevant,Profit taking pullback (-9%) after massive +30% surge on Partnership news. Healthy correction.,0.4,0.7,0.4,0.2,0.3,0.0,0,0.7,0.3,,,-0.0343823427061102,-0.2574698807648957,942238.6590000005,,,
2026-01-07,ALMS,2026-01-07T12:47:36.372093,-26.89,0.15,-0.0090355168798832,No,-0.6,0.06,Medium,High,41.1,10 checked / 5+ relevant,Drop driven by $175M public offering announcement despite positive Phase 3 envudeucitinib data. Classic sell-the-news/dilution event.,0.8,1.0,0.7,0.9,1.0,0.2,1,0.2,0.8,,,0.0163095737614004,-0.0458680384311516,51424614.52749999,,,
2026-01-07,DRUG,2026-01-07T12:47:36.372093,-22.2,0.06,0.0214466991698105,No,-0.6,-0.14,Medium,High,33.2,10 checked / 5+ relevant,Drop due to $100M public offering announced alongside positive Phase 2 epilepsy data. Market focused on dilution.,0.7,1.0,0.6,0.9,1.0,0.1,1,0.3,0.7,,,-0.0016736475591918,-0.0833037665944892,17599691.526333336,,,
2026-01-07,SION,2026-01-07T12:47:36.372093,-7.85,0.03,0.045270523502857,No,0.42,-0.27,High,Medium,62.5,10 checked / 5+ relevant,Insider selling pressure and recent downgrades weighing on sentiment despite upcoming conference.,0.6,0.8,0.5,0.6,0.4,0.3,0,0.4,0.5,,,-0.0266263558333491,-0.0829761080917962,13423306.9425,,,
2026-01-07,THH,2026-01-07T12:47:36.372093,-14.69,-0.19,0.0154445174829463,No,0.27,-0.13,High,Low,50.9,10 checked / 5+ relevant,No specific news found. Drop appears technical or related to post-IPO volatility.,0.3,0.2,0.2,0.1,0.1,0.0,0,0.5,0.2,,,-0.0507562489354086,-0.0426236705339317,2258347.217673333,,,
2026-01-07,CCCX,2026-01-07T12:47:36.372093,-10.15,-0.24,0.0721768093046983,No,0.46,-0.4,Medium,Medium,47.9,10 checked / 5+ relevant,Drop on S-4 filing for merger with Infleqtion. SPAC merger risks and 'sell the news' logic applying.,0.5,1.0,0.4,0.8,0.9,0.1,0,0.4,0.4,,,-0.0569916324422132,-0.0996530363500782,28986777.7345,,,
2026-01-07,ANRO,2026-01-07T12:47:36.372093,-8.94,-0.29,0.003215864932749,No,0.25,0.0,High,Low,48.6,10 checked / 5+ relevant,No specific news today. Director options grant (Jan 6) is routine. Likely technical drift.,0.2,0.3,0.2,0.1,0.1,0.0,0,0.5,0.1,,,-0.0730202055291295,-0.0431736929235188,6323013.731333333,,,
2026-01-07,VSNT,2026-01-07T12:47:36.372093,-10.27,-0.57,0.0572797730815748,No,0.36,-0.47,Medium,High,26.8,10 checked / 5+ relevant,Continued selling pressure following spin-off from Comcast. Structural flow/overhang and sector skepticism.,0.6,0.9,0.5,0.4,0.8,0.0,0,0.4,0.5,,,-0.5444186282600519,1.0535761425393626,894324507.93,,,
2026-01-07,PBF,2026-01-07T12:47:36.372093,-7.98,-0.66,0.0575938790304451,No,-0.6,-0.47,Low,High,7.4,10 checked / 5+ relevant,Refinery (Martinez) restart delayed to Feb/Mar 2026. Fundamental negative impacting near-term earnings.,0.8,1.0,0.7,0.9,1.0,0.0,1,0.2,0.8,,,-0.0998141319329917,0.1369559548600572,88014829.86850001,,,
